EA201592032A1 - Полиморфные формы гидрохлорида нилотиниба - Google Patents

Полиморфные формы гидрохлорида нилотиниба

Info

Publication number
EA201592032A1
EA201592032A1 EA201592032A EA201592032A EA201592032A1 EA 201592032 A1 EA201592032 A1 EA 201592032A1 EA 201592032 A EA201592032 A EA 201592032A EA 201592032 A EA201592032 A EA 201592032A EA 201592032 A1 EA201592032 A1 EA 201592032A1
Authority
EA
Eurasian Patent Office
Prior art keywords
polymorphic forms
nilotinib hydrochloride
nilotinib
hydrochloride
forms
Prior art date
Application number
EA201592032A
Other languages
English (en)
Inventor
Вишвешвар Педди
Раманаяах Ченнуру
Сривидиа Рамакришнан
Original Assignee
Др. Реддис Лабораторис Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Др. Реддис Лабораторис Лимитед filed Critical Др. Реддис Лабораторис Лимитед
Publication of EA201592032A1 publication Critical patent/EA201592032A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Кристаллические формы R5, R5a, R5b и R6 гидрохлорида нилотиниба и способы их получения.
EA201592032A 2013-04-24 2014-04-23 Полиморфные формы гидрохлорида нилотиниба EA201592032A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1795CH2013 2013-04-24
PCT/IB2014/060935 WO2014174456A2 (en) 2013-04-24 2014-04-23 Polymorphic forms of nilotinib hydrochloride

Publications (1)

Publication Number Publication Date
EA201592032A1 true EA201592032A1 (ru) 2016-04-29

Family

ID=51792459

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201592032A EA201592032A1 (ru) 2013-04-24 2014-04-23 Полиморфные формы гидрохлорида нилотиниба

Country Status (11)

Country Link
US (2) US9580408B2 (ru)
EP (2) EP2989090A4 (ru)
JP (2) JP2016522182A (ru)
CN (1) CN105324375A (ru)
AU (1) AU2014259029B2 (ru)
BR (1) BR112015026827A2 (ru)
CA (1) CA2912902A1 (ru)
EA (1) EA201592032A1 (ru)
MX (1) MX2015014897A (ru)
NZ (1) NZ714378A (ru)
WO (1) WO2014174456A2 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014059518A1 (en) 2012-10-15 2014-04-24 Apotex Technologies Inc. Solid forms of nilotinib hydrochloride
NZ714378A (en) 2013-04-24 2020-08-28 Dr Reddys Laboratories Ltd Polymorphic forms of nilotinib hydrochloride
EP3177610A4 (en) * 2014-08-08 2018-01-10 Dr. Reddy's Laboratories Ltd. Process for the preparation of polymorphic forms of nilotinib
CN106478603B (zh) * 2015-08-25 2021-01-01 江苏豪森药业集团有限公司 尼洛替尼盐酸盐的新晶型及其制备方法和医药用途
EP3404025B1 (en) * 2017-05-16 2019-12-04 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure nilotinib and its salt
CZ2017821A3 (cs) 2017-12-20 2019-07-03 Zentiva, K.S. Léková forma obsahující krystalický nilotinib
TWI770624B (zh) 2018-06-15 2022-07-11 漢達生技醫藥股份有限公司 尼洛替尼十二烷基硫酸鹽在製備用於治療慢性骨髓性白血病之劑型的用途
US20210380557A1 (en) * 2018-11-05 2021-12-09 Laurus Labs Limited Crystalline form of nilotinib hydrochloride, process for its preparation and pharmaceutical composition containing the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GT200600316A (es) * 2005-07-20 2007-04-02 Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
GT200600315A (es) * 2005-07-20 2007-03-19 Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida
US20100016590A1 (en) * 2008-07-17 2010-01-21 Teva Pharmaceutical Industries Ltd. Nilotinib intermediates and preparation thereof
PL2262793T3 (pl) * 2008-11-05 2013-01-31 Teva Pharma Formy krystaliczne nilotynibu HCL
WO2011033307A1 (en) * 2009-09-17 2011-03-24 Generics [Uk] Limited Nilotinib dihydrochloride salt
IN2010KO00035A (ru) * 2010-01-15 2016-09-02
EP2571863B1 (en) 2010-06-21 2015-09-23 Teva Pharmaceutical Industries Ltd. Nilotinib salts and crystalline forms thereof
CN102453024B (zh) 2010-10-27 2014-09-03 浙江九洲药业股份有限公司 一种尼罗替尼盐酸盐晶型及其制备方法
US8703788B2 (en) 2010-11-26 2014-04-22 Bandi Parthasaradhi Reddy Polymorph of nilotinib hydrochloride
US9061028B2 (en) 2012-02-15 2015-06-23 Natco Pharma Limited Process for the preparation of Nilotinib
NZ714378A (en) 2013-04-24 2020-08-28 Dr Reddys Laboratories Ltd Polymorphic forms of nilotinib hydrochloride

Also Published As

Publication number Publication date
EP3461818A1 (en) 2019-04-03
MX2015014897A (es) 2016-03-07
BR112015026827A2 (pt) 2017-09-05
CN105324375A (zh) 2016-02-10
AU2014259029B2 (en) 2018-08-16
EP2989090A2 (en) 2016-03-02
WO2014174456A3 (en) 2015-02-19
JP2016522182A (ja) 2016-07-28
JP2019014762A (ja) 2019-01-31
AU2014259029A1 (en) 2015-12-10
US9580408B2 (en) 2017-02-28
US20160130252A1 (en) 2016-05-12
US20170260162A1 (en) 2017-09-14
EP2989090A4 (en) 2017-01-18
CA2912902A1 (en) 2014-10-30
WO2014174456A2 (en) 2014-10-30
NZ714378A (en) 2020-08-28
US9981947B2 (en) 2018-05-29

Similar Documents

Publication Publication Date Title
EA201592032A1 (ru) Полиморфные формы гидрохлорида нилотиниба
EA201792535A1 (ru) Гетероциклические амиды в качестве ингибиторов киназ
EA201591420A1 (ru) Гетероарильные соединения и их применение
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
CR20150524A (es) Compuestos de heteroarilo y sus usos
EA201692338A1 (ru) Соединения 5-хлор-дифторметоксифенил-пиразолопиримидина, представляющие собой ингибиторы янус-киназы
EA201790395A1 (ru) Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
ZA201702737B (en) Crystalline forms of 5-chloro-n4-[-2-(dimethylphosphoryl) phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl) piperidin-1-yl] phenyl}pyrimidine-2,4-diamine
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA202091397A1 (ru) Бензохинолоновые ингибиторы vmat2
IL246385A0 (en) Crystalline forms of efitinib di-malate
MA51554A (fr) Anticorps il-6 améliorés
IN2013MU00848A (ru)
FI20135866L (fi) Mikrobiologinen keratiinin prosessointi
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
EA201690263A1 (ru) Улучшенные способы получения перампанеля
IN2013MU01113A (ru)
EA201691203A1 (ru) Твёрдые формы тенофовира
IN2013MU04056A (ru)
ECSP17015682A (es) Inhibidores cristalinos de bace
EA201691112A1 (ru) Образование антител ex vivo
MX2016004573A (es) Inhibidores de nsp4 y metodos de uso.
EA201391421A1 (ru) Пролекарства d-гамма-глутамил-d-триптофана и d-гамма-глутамил-l-триптофана
IN2014CH01391A (ru)